BZYR (Burzynski Research Institute) EBIT: $-1.29 Mil (TTM As of Nov. 2025)


What is Burzynski Research Institute EBIT?

Burzynski Research Institute BZYR EBIT is $-1.29 Mil as of Nov. 2025.

Burzynski Research Institute's earnings before interest and taxes (EBIT) for the three months ended in Nov. 2025 was $-0.33 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Nov. 2025 was $-1.29 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Burzynski Research Institute's annualized ROC % for the quarter that ended in Nov. 2025 was %. Burzynski Research Institute's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2025 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Burzynski Research Institute's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Nov. 2025 was -160.88%.

Burzynski Research Institute  (OTCPK:BZYR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Burzynski Research Institute's annualized ROC % for the quarter that ended in Nov. 2025 is calculated as:

ROC % (Q: Nov. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Aug. 2025 ) + Invested Capital (Q: Nov. 2025 ))/ count )
=-1.316 * ( 1 - 0% )/( (0 + 0)/ 2 )
=-1.316/0
= %

where

Invested Capital(Q: Aug. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.001 - 0.071 - ( 0.001 - max(0, 0.071 - 0.001+0.001))
=0

Invested Capital(Q: Nov. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.002 - 0.07 - ( 0.002 - max(0, 0.07 - 0.002+0.002))
=0

Note: The Operating Income data used here is four times the quarterly (Nov. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Burzynski Research Institute's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Nov. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Aug. 2025  Q: Nov. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.316/( ( (0 + max(-0.071, 0)) + (0 + max(-0.07, 0)) )/ 2 )
=-1.316/( ( 0 + 0 )/ 2 )
=-1.316/0
= %

where Working Capital is:

Working Capital(Q: Aug. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.071 + 0 + 0)
=-0.071

Working Capital(Q: Nov. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.07 + 0 + 0)
=-0.07

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Nov. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Burzynski Research Institute's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Nov. 2025 )
=-1.287/0.800
=-160.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Burzynski Research Institute EBIT Related Terms

Burzynski Research Institute EBIT Historical Data

* Premium members only.

The historical data trend for Burzynski Research Institute's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Burzynski Research Institute EBIT Chart

Burzynski Research Institute Annual Data
Trend Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.30 -0.98 -0.92 -1.34 -1.39

Burzynski Research Institute Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.35 -0.29 -0.33 -0.33 -0.33

BZYR vs CLSDQ, ZVSA, ADAPY: EBIT Comparison

For the Biotechnology subindustry, Burzynski Research Institute's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Burzynski Research Institute EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Burzynski Research Institute's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Burzynski Research Institute's EV-to-EBIT falls into.


Burzynski Research Institute EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-1.29 Mil mean?
Burzynski Research Institute (BZYR) has a EBIT of $-1.29 Mil as of Nov. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Burzynski Research Institute.
Is Burzynski Research Institute's EBIT too high?
Burzynski Research Institute's current EBIT is $-1.29 Mil.
How does Burzynski Research Institute's EBIT compare to CLSDQ and ZVSA?
Burzynski Research Institute's EBIT of $-1.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Burzynski Research Institute. Burzynski Research Institute's current EBIT is $-1.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burzynski Research Institute stock overvalued right now?
Burzynski Research Institute (BZYR) has a current EBIT of $-1.29 Mil. The current EBIT is $-1.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Burzynski Research Institute (BZYR), the current EBIT is $-1.29 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Burzynski Research Institute Business Description

Address 9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc operates as a research and development facility of Antineoplaston drugs currently being tested for the use in the treatment of cancer, and provides consulting services.